Ralliant Corporation (NYSE:RAL) Receives $57.89 Consensus Target Price from Analysts

Shares of Ralliant Corporation (NYSE:RAL) have earned a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $58.00.

Several brokerages have weighed in on RAL. Oppenheimer upped their target price on shares of Ralliant from $55.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Ralliant in a research note on Monday, December 29th. Truist Financial initiated coverage on Ralliant in a research note on Friday, December 12th. They issued a “buy” rating and a $62.00 price objective for the company. Citigroup raised Ralliant from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $53.00 to $61.00 in a report on Monday, December 8th. Finally, Royal Bank Of Canada boosted their target price on Ralliant from $45.00 to $52.00 and gave the stock a “sector perform” rating in a research report on Friday, November 7th.

Ralliant Stock Performance

Ralliant stock opened at $51.28 on Tuesday. The firm has a market capitalization of $5.78 billion and a P/E ratio of 40.38. Ralliant has a one year low of $40.70 and a one year high of $55.08. The firm has a fifty day simple moving average of $49.15. The company has a current ratio of 1.49, a quick ratio of 1.03 and a debt-to-equity ratio of 0.39.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.02. The company had revenue of $529.10 million during the quarter, compared to analysts’ expectations of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 23rd. Investors of record on Monday, December 8th were paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Monday, December 8th. Ralliant’s dividend payout ratio is presently 15.75%.

Hedge Funds Weigh In On Ralliant

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Westfuller Advisors LLC acquired a new position in shares of Ralliant during the 3rd quarter worth approximately $26,000. Palisade Asset Management LLC acquired a new stake in shares of Ralliant during the third quarter valued at $26,000. ST Germain D J Co. Inc. acquired a new stake in shares of Ralliant during the second quarter valued at $27,000. Manchester Capital Management LLC acquired a new position in Ralliant in the 2nd quarter valued at about $29,000. Finally, UMB Bank n.a. purchased a new position in Ralliant in the 3rd quarter valued at about $29,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.